Sector News

Regeneron’s Eylea snags pre-filled syringe approval as Novartis rival looms

August 14, 2019
Life sciences

Eye med Eylea has been a blockbuster sales force for Regeneron, but Novartis’ challenger brolucizumab is on the horizon. Could a new delivery option give Eylea a leg up?

That’s what Regeneron’s hoping. The FDA Tuesday approved a new pre-filled injector for 2-milligram single doses of Eylea to treat patients with wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.

The drugmaker touted the new approval as a game-changer for physicians, taking multiple preparation steps out of the original vial dose regimen. Eylea is now the only drug approved to treat four retinal diseases with a pre-filled injector, and the newest green light should help it secure its place as the top-performing wet AMD drug on the market as competitors loom.

Novartis’ brolucizumab, a wannabe rival in wet AMD, is under priority review from the FDA, and it could steal the limelight from Eylea and its only approved competitor, Roche’s Lucentis. Novartis’ drug boasts strong head-to-head data against Eylea, including wins against the older drug in reducing retinal fluid and central subfield thickness.

But Regeneron hasn’t taken that challenge sitting down. In May, Eylea received an FDA nod to treat all forms of diabetic retinopathy, a condition that affects about 8 million people worldwide and is the leading cause of blindness in U.S. adults, the company said.

That new indication helped drive Eylea sales up 17% in the second quarter to $1.16 billion. Those sales represent a significant chunk of the drugmaker’s total $1.9 billion in the quarter.

It also followed positive results from the drug’s phase 3 trial dubbed Panorama, which showed an 85% and 88% risk reduction for diabetic retinopathy patients developing proliferative diabetic retinopathy (PDR) at the one-year mark when dosing every 16 and eight weeks, respectively. Twenty percent of untreated patients developed PDR, which causes abnormal blood vessel growth on retinas and potentially vision loss, at the one-year mark, the company said.

Strong sales have been a boon for Regeneron as another pillar of its growth strategy—an antibody partnership with Sanofi on PCSK9 inhibitor Praluent and Dupixent—is just now turning a profit.

Fueled by Dupixent’s $557 million in second-quarter sales—a 166% increase—Regeneron last week reported that its Sanofi partnership posted a $39 million profit, a big turnabout from the same period last year, when it cost Regeneron $69 million.

By: Kyle Blankenship

Source: Fierce Pharma

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.